Skip to main content
SpringerLink
Log in

Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Favorable acute myeloid leukemia (AML) patients (pts.) demonstrate a relatively good outcome with standard induction; thus, pts. are generally not addressed to allogeneic transplant in first remission. However, it is not clear if also in a real-life setting, the outcome is homogeneous in the different favorable molecular groups and which are the parameters significantly associated to an increased relapse risk, useful to suggest the need of an intensified approach. In order to clarify this point, we collected clinical data on consecutive unselected AML pts. assigned to favorable category (modified ELN 2010 due to the inclusion of double-mutated CEBPA-positive cases), diagnosed and treated in six centers of the Italian network Rete Ematologica Lombarda (REL) from 2007 to 2015. We assessed response (CR, mCR), relapse rate (CIR), and outcome (OS, DFS) after first-line treatment. A total of 201 pts. was studied and the analysis was performed globally and in each molecular group: t(8;21)(q22;q22)/RUNX1-RUNX1T1 (30 pts., 14.9%), inv. (16)(p13q22) or t(16;16)(p13q22)/CBFB-MIH11 (35 pts., 17.4%), normal karyotype and mutated NPM1 and negative FLT3-ITD (116 pts., 57.7%) or double-mutated CEBPA (CEBPAdm) (20 pts., 10%). Complete remission (CR) was obtained in 188 pts. (93.5%), molecular CR (mCR) in 114 (67.5%); After a median follow-up of 2.4 years, cumulative incidence of relapse (CIR) was documented in 78 of 188 responding pts. (41%) after a median time of 11.3 months. CIR was higher in the CBFB-MIH11 group, in pts. achieving only a hematological response without mCR (72.1 vs 28.1%, p < 0.001), in older pts. and it resulted independently associated with a lower median cytarabine cumulative dose (CCD). Median OS was not reached: after 5 years it was 66.3%, and median DFS was 5.3 years, both without difference among groups. Molecular CR reached at any time, during or after the end of first-line treatment, was significantly associated with better DFS, and in particular, mCR assessed at the end of treatment was confirmed in multivariate analysis as an independent prognostic factor both for DFS and OS. In conclusion, the present study confirms in a real-life context the overall good prognosis of favorable-risk AML; the achievement of any molecular negativity during first-line treatment, particularly when assessed at the end of treatment, is associated with lower relapse and better survival. Increasing age at diagnosis has a negative prognostic impact, while CCD higher than 18 g/sqm is associated with better outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Dohner H, Estey EH, Amadori S et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 115:453–474

    Article  Google Scholar 

  2. Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J, Qumsiyeh M, Moore JO, Mayer RJ, Davey F, Schiffer CA, Bloomfield CD (1999) Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17:3767–3775

    Article  CAS  Google Scholar 

  3. Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD (2005) Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 23(24):5705–5717

    Article  Google Scholar 

  4. Burnett K, Russell NH, Hills RK et al (2013) Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 31:3360–3368

    Article  CAS  Google Scholar 

  5. Dohner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. NEJM 373:1136–1152

    Article  Google Scholar 

  6. Mrózek K, Marcucci G, Nicolet D et al (2012) Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. JCO 30:4515–4523

    Article  Google Scholar 

  7. Willekens C, Blanchet O, Renneville A, on behalf of the French AML Intergroup (2016) Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial. Haematologica 101:328–335

    Article  CAS  Google Scholar 

  8. Zhu H-H, Zhang X-H, Qin Y-Z, Liu DH, Jiang H, Chen H, Jiang Q, Xu LP, Lu J, Han W, Bao L, Wang Y, Chen YH, Wang JZ, Wang FR, Lai YY, Chai JY, Wang LR, Liu YR, Liu KY, Jiang B, Huang XJ (2013) MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood 121(20):4056–4062

    Article  CAS  Google Scholar 

  9. Yin LJA, O’Brien MA, Hills RK et al (2012) Minimal residual disease monitoring by quantitative RT-PCR in core binding factorAMLallows risk stratification and predicts relapse: results of the United Kingdom MRCAML-15 trial. Blood 120(14):2826–2835

    Article  CAS  Google Scholar 

  10. Corbacioglu A, Scholl C, Schlenk RF, Eiwen K, du J, Bullinger L, Fröhling S, Reimer P, Rummel M, Derigs HG, Nachbaur D, Krauter J, Ganser A, Döhner H, Döhner K (2010) Prognostic impact of minimal residual disease in CBFB-MIH11–positive acute myeloid leukemia. J Clin Oncol 28:3724–3729

    Article  CAS  Google Scholar 

  11. Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, Blanchet O, Cayuela JM, Recher C, Raffoux E, Delaunay J, Pigneux A, Bulabois CE, Berthon C, Pautas C, Vey N, Lioure B, Thomas X, Luquet I, Terre C, Guardiola P, Bene MC, Preudhomme C, Ifrah N, Dombret H, for the French AML Intergroup (2013) Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 121(12):2213–2223

    Article  CAS  Google Scholar 

  12. Krönke J, Schlenk RF, Jensen KO, Tschürtz F, Corbacioglu A, Gaidzik VI, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, Kindler T, Salih HR, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler HG, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K (2011 Jul 1) Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol 29(19):2709–2716

    Article  Google Scholar 

  13. Shayegi N, Kramer M, Bornhauser M, Schaich M, Schetelig J, Platzbecker U, Rollig C, Heiderich C, Landt O, Ehninger G, Thiede C, on behalf of the Study Alliance Leukemia (SAL), on behalf of the Study Alliance Leukemia (SAL) (2013) The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood 122(1):83–92

    Article  CAS  Google Scholar 

  14. Hubmann M, Köhnke T, Hoster E et al (2014) Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse. Haematologica 99(8):1317–1325

    Article  CAS  Google Scholar 

  15. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD, International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642–4649

    Article  Google Scholar 

  16. Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Gameiro P, Pisa P, Gonzalez M, Bartram CR, Panzer-Grümayer ER, Biondi A, San Miguel JF, van Dongen J (1999) Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 13(1):110–118

    Article  CAS  Google Scholar 

  17. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, Wermke M, Bornhäuser M, Ritter M, Neubauer A, Ehninger G, Illmer T (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogeneous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99(12):4326–4335

    Article  CAS  Google Scholar 

  18. Noguera NI, Ammatuna E, Zangrilli D, Lavorgna S, Divona M, Buccisano F, Amadori S, Mecucci C, Falini B, Lo-Coco F (2005 Aug) Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. Leukemia 19(8):1479–1482

    Article  CAS  Google Scholar 

  19. Gorello P, Cazzaniga G, Alberti F, Dell'Oro MG, Gottardi E, Specchia G, Roti G, Rosati R, Martelli MF, Diverio D, Coco FL, Biondi A, Saglio G, Mecucci C, Falini B (2006) Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 20(6):1103–1108

    Article  CAS  Google Scholar 

  20. Lin LI, Chen CY, Lin DT, Tsay W, Tang JL, Yeh YC, Shen HL, Su FH, Yao M, Huang SY, Tien HF (2005 Feb 15) Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 11(4):1372–1379

    Article  CAS  Google Scholar 

  21. Dohner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447

    Article  Google Scholar 

  22. Ahn J-S, Kim J-Y, Kim H-J et al (2016) Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant. Ann Hematol 95(2):301–310

    Article  CAS  Google Scholar 

  23. Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, Råcil Z, Rowe JM, Russell N, Mohty M, Löwenberg B, Socié G, Niederwieser D, Ossenkoppele GJ (2012) The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 9(10):579–590

    Article  CAS  Google Scholar 

  24. Nguyen S, Leblanc T, Fenaux P, Witz F, Blaise D, Pigneux A, Thomas X, Rigal-Huguet F, Lioure B, Auvrignon A, Fière D, Reiffers J, Castaigne S, Leverger G, Harousseau JL, Socié G, Dombret H (2002) A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood 99:3517–3523

    Article  CAS  Google Scholar 

  25. Cairoli C, Beghini A, Grillo G et al (2006) Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 107:3463–3468

    Article  CAS  Google Scholar 

  26. Cairoli R, Beghini A, Turrini M, Bertani G, Morra E (2012) Prognostic markers in AML: focus on CBFL. Leukemia Suppl 1:S12–S13

    Article  CAS  Google Scholar 

  27. Hoyos M, Nomdedeu JF, Esteve J, Duarte R, Ribera JM, Llorente A, Escoda L, Bueno J, Tormo M, Gallardo D, de Llano MPQ, Martí JM, Aventín A, Mangues R, Brunet S, Sierra J (2013) Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease. Eur J Haematol 91:209–218

    Article  CAS  Google Scholar 

  28. Dohner K, Schlenk RF, Habdank M et al (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106:3740–3746

    Article  Google Scholar 

  29. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD (2010) Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and MICRORNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 28:596–604

    Article  CAS  Google Scholar 

  30. Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths M, Solomon E, McCaughan F, Linch DC, Gale RE, Vyas P, Freeman SD, Russell N, Burnett AK, Grimwade D, UK National Cancer Research Institute AML Working Group (2016) Assessment of minimal residual disease in standard-risk AML. N Engl J Med 374:422–433

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy

    Patrizia Zappasodi, Matteo Da Vià, Barbara Rocca, Celeste Calvello, Mario Cazzola & Carlo Castagnola

  2. Department of Hematology, Niguarda Ca’ Granda Hospital, Milan, Italy

    Laura Marbello, Valentina Mancini & Emanuele Ravano

  3. Department of Hematology, Spedali Civili, Brescia, Italy

    Erika Borlenghi, Elisa Cerqui & Giuseppe Rossi

  4. Department of Hematology, Ospedale San Gerardo, Monza, Italy

    Monica Fumagalli

  5. Hematology and Bone Marrow Unit, San Raffaele Scientific Institute, Milan, Italy

    Massimo Bernardi

  6. Department of Hematology, Foundation, IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

    Nicola Fracchiolla

  7. Department of Molecular Medicine, University of Pavia, Pavia, Italy

    Virginia Valeria Ferretti

Authors
  1. Patrizia Zappasodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Marbello
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erika Borlenghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Monica Fumagalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Massimo Bernardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nicola Fracchiolla
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Valentina Mancini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Matteo Da Vià
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Emanuele Ravano
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Elisa Cerqui
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Virginia Valeria Ferretti
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Barbara Rocca
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Celeste Calvello
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Mario Cazzola
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Carlo Castagnola
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Giuseppe Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrizia Zappasodi.

Ethics declarations

The study was approved by the ethical committees of all participating institutions.

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zappasodi, P., Marbello, L., Borlenghi, E. et al. Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network. Ann Hematol 97, 2107–2115 (2018). https://doi.org/10.1007/s00277-018-3424-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-018-3424-4

Keywords

Search

Navigation